Neuroleptics and dopamine transporters

Neurochemical Research

Volumn 23, Issue 1, 1998, Pages 73-80

  Reader, Tomás A ^a   Ase, Ariel R ^a   Huang, Ning ^a,b   Hébert, Caroline ^a   Van Gelder, Nico M ^a,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Clozapine; Dopamine uptake sites; Haloperidol; Raclopride; SCH23390

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; HALOPERIDOL; NEUROLEPTIC AGENT; RACLOPRIDE;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG EFFECT; DRUG MECHANISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEOSTRIATUM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; NEOSTRIATUM; NUCLEUS ACCUMBENS; OLFACTORY PATHWAYS; PROSENCEPHALON; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SUBSTANTIA NIGRA; TEGMENTUM MESENCEPHALI;

EID: 0031894580     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022405621365     Document Type: Article

References (40)

1. Van Rossum, J. M. 1966. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 160:492-494.
2. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. 1976. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-721.
3. Seeman P. 1987. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152.
4. 2 pKi values. J. Pharmacol. Exp. Ther. 251:238-246.
5. Chouinard, G., Vainer, J. L., Bélanger, M.-C., Turnier, L., Beaudry, P., Roy, J.-Y., and Milner, R. 1994. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Progr. Neuro-Psychopharmacol. & Biol. Psychiat. 18:1129-1141.
6. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: (Suppl.) 28-31.
7. 1 receptors drugs that attenuate both pos-itive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 2:191-199.
8. 2-receptor occupancy during antipsychotic drug treatment. Progr. Neuro-Psychopharmacol. & Biol. Psychiatr. 14: 759-767.
9. Farde, L., and Nordström, A. L. 1992. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatr. 160:(Suppl. 17) 30-33.
10. O'Dell, S. J., La Hoste, G. J., Winmark, C. B., Shapiro, R. M., Potkin, S. G., and Marshal, J. F. 1990. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6:146-153.
11. See, R. E., Toga, A. W., and Ellison, G. 1990. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. Neural Transm. 82:93-109.
12. Snyder, S. H. 1970. Putative neurotransmitter in the brain: selective neuronal uptake, subcellular localization and interactions with centrally acting drugs. Biol. Psychiat. 2:367-389.
13. Iversen, L. L. 1973. Catecholamine uptake processes. Br. Med. Bull. 29:130-135.
14. Raiteri, M., Cerrito, F., Cervoni, A. M., del Carmine, R., Ribera, M. T., and Levi, G. 1978. Studies on dopamine uptake and release in synaptosomes. Adv. Biochem. Psychopharmacol. 19:35-36.
15. Giros, B., Mestikawy, S. E., Godinot, N., Zheng, K., Han, H., Yang-Feng, T., and Caron, M. G. 1992. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molec. Pharmacol. 42:383-390.
16. Giros, B., Wang, Y.-M., Suter, S., McLeskey, S. B., Pifi, C., and Caron, M. G. 1994. Delineation of discrete domains for substrate, cocaine, and tricyclic anti-depressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269: 15985-15988.
17. Vandenbergh, S. J., Persico, A. M., and Uhl, G. R. 1992. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic Taq I RFLPS. Molec. Brain Res. 15:161-166.
18. 3H]GBR 12935 binding. Molec. Pharmacol. 45: 125-135.
19. Amara, S. G., and Kuhar, M. J. 1993. Neurotransmitter transporters: Recent progress. Annu. Rev. Neurosci. 16:73-93.
20. 2 receptors: homogenate binding and autoradiographic studies. Neurochem. Int. 30:277-290.
21. Paxinos, G., and Watson, C. 1982. The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney.
22. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Molec. Pharmacol. 47:779-786.
23. 125I]RTI-121. Synapse 21:364-372.
24. Carli, M., Morissette, M., Hébert, C., Di Paolo, T., and Reader, T. A. 1997. Effects of a chronic lithium treatment on central dopamine transporters. Biochem. Pharmacol. (in press).
25. 3H]SCH23390. Eur. J. Pharmacol. 108:323-325.
26. 2 receptors in adult rat neostriatum after neonatal dopamine denervation. Correlation of quantitative data from ligand binding autoradiography, in situ hybridization and iontophoresis. Neuroscience 57:635-648.
27. Reader, T. A., Radja, F., Dewar, K. M., and Descarries, L. 1995. Denervation, hyperinnervation and interactive regulation of dopamine and serotonin receptors. Ann. N. Y. Acad. Sci. 757:293-310.
28. 3H]raclopride. Neurosci. Lett. 66:85-90.
29. Barlow, R. B. 1983. Biodata Handling with Microcomputers. Elsevier Science Publishers, Amsterdam.
30. Frank, H., and Althoen, S. C. 1994. Statistics: Concepts and Applications. Cambridge University Press, New York.
31. 2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:3177-3188.
32. 1-dopamine agonist following repeated adminis-tration to neonatal 6-OHDA-lesioned rats. J. Neurosci. 9:125-133.
33. 1 receptors in cerebral cortex and neostriatum: Evidence for heterogeneity in affinity states and cortical distribution. J. Neurochem. 50:451-463.
34. 2 antagonism in extrapyramidal functions. Br. J. Psychiatr. 160:(Suppl 17) 34-37.
35. 2 receptor isoforms in various cerebral tissues. J. Neurochem. 58:673-679.
36. Allikmets, L. H., Zarkovsky, A. M., and Nurk, A. M. 1981. Changes in catalepsy and receptor sensitivity following chronic neuroleptic treatment. Eur. J. Pharmacol. 75:145-147.
37. 2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. J. Pharmacol. Exp. Ther. 261:1282-1290.
38. Kuhar, M. J., Sanchez-Roa, P. M., Wong, D. F., Dannals, R. F., Grigoriadis, D. E., Lew, R., and Milberger, M. 1990. Dopamine transporter: biochemistry, pharmacology and imaging. Eur. Neurol. 30(Suppl):15-20.
39. Kennedy, L. T., and Hanbauer, I. 1983. Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites. J. Neurochem. 42:172-178.
40. Reith, M. E. A., Meisler, B. E., Sershen, H., and Lajtha, A. 1986. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 35:1123-1129.